Biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) seem to be the most effective treatments for ...

Ustekinumab, a monoclonal antibody, is approved for the treatment of psoriasis vulgaris and psoriatic arthritis.

Patients with uveitis had a higher risk for psoriatic arthritis and psoriasis, whereas those with psoriatic arthritis had a higher risk for uveitis.

Sandoz announced the European launch of its Pyzchiva (ustekinumab) autoinjector. This is the first ustekinumab biosimilar in ...

Teva and Alvotech announced that the U.S. Food and Drug Administration (FDA) approved SELARSDI (ustekinumab-aekn) injection as ...

On May 22, 2025, the FDA approved Bio-Thera Solutions and Hikma Pharmaceuticals’ ustekinumab biosimilar, STARJEMZA® (ustekinumab-hmny) ...

New study shows a subset of psoriatic arthritis patients can achieve long-term remission without DMARDs. Learn who benefits ...

After the launch of Ustekinumab, a biosimilar of Stelara, in the United States and Europe, Biocon Biologics’ biosimilar drug ...

The U.K.’s Medicines and Healthcare products Regulatory Agency has approved guselkumab, or Tremfya, to treat Crohn’s disease ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya) for the treatment of Crohn’s ...

Metabolic syndrome was independently associated with elevated levels of pain catastrophizing among patients with psoriatic arthritis and may impact disease activity. Metabolic syndrome (MetS) is ...